Integrated Microfluidic Card with TaqMan Probes and High-Resolution Melt Analysis To Detect Tuberculosis Drug Resistance Mutations across 10 Genes
Open Access
- 1 May 2015
- journal article
- research article
- Published by American Society for Microbiology in mBio
- Vol. 6 (2) , e02273-14-e02273
Abstract
Genotypic methods for drug susceptibility testing of Mycobacterium tuberculosis are desirable to speed the diagnosis and proper therapy of tuberculosis (TB). However, the numbers of genes and polymorphisms implicated in resistance have proliferated, challenging diagnostic design. We developed a microfluidic TaqMan array card (TAC) that utilizes both sequence-specific probes and high-resolution melt analysis (HRM), providing two layers of detection of mutations. Twenty-seven primer pairs and 40 probes were designed to interrogate 3,200 base pairs of critical regions of the inhA , katG , rpoB , embB , rpsL , rrs , eis , gyrA , gyrB , and pncA genes. The method was evaluated on 230 clinical M. tuberculosis isolates from around the world, and it yielded 96.1% accuracy (2,431/2,530) in comparison to that of Sanger sequencing and 87% accuracy in comparison to that of the slow culture-based susceptibility testing. This TAC-HRM method integrates assays for 10 genes to yield fast, comprehensive, and accurate drug susceptibility results for the 9 major antibiotics used to treat TB and could be deployed to improve treatment outcomes. IMPORTANCE Multidrug-resistant tuberculosis threatens global tuberculosis control efforts. Optimal therapy utilizes susceptibility test results to guide individualized treatment regimens; however, the susceptibility testing methods in use are technically difficult and slow. We developed an integrated TaqMan array card method with high-resolution melt analysis that interrogates 10 genes to yield a fast, comprehensive, and accurate drug susceptibility result for the 9 major antituberculosis antibiotics.Keywords
This publication has 35 references indexed in Scilit:
- Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysisClinical Infectious Diseases, 2014
- Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant TuberculosisClinical Infectious Diseases, 2014
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLOS Medicine, 2012
- New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB MutationsPLOS ONE, 2012
- Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Evaluation of the Analytical Performance of the Xpert MTB/RIF AssayJournal of Clinical Microbiology, 2010
- Annual Report 2010Annual Report 2016, 2010
- Performance Assessment of the GenoType MTBDR plus Test and DNA Sequencing in Detection of Multidrug-Resistant Mycobacterium tuberculosisJournal of Clinical Microbiology, 2009
- Comparison of Two Commercially Available DNA Line Probe Assays for Detection of Multidrug-Resistant Mycobacterium tuberculosisJournal of Clinical Microbiology, 2006
- Evaluation of a New Line Probe Assay for Rapid Identification of gyrA Mutations in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2005